Axsome Therapeutics, listed on NASDAQ:AXSM, is a biopharmaceutical company focused on developing therapies for central nervous system disorders. The company is set to release its quarterly earnings on February 23, 2026. Wall Street anticipates an earnings per share (EPS) of -$0.70 and revenue of approximately $193.3 million.
The upcoming earnings report is crucial for AXSM, as it is expected to surpass earnings estimates, potentially boosting its stock price. The anticipated year-over-year increase in earnings is driven by higher revenues for the quarter ending December 2025. If Axsome's actual results exceed expectations, it could positively impact the stock price.
Despite a negative P/E ratio of -40.57, indicating current unprofitability, Axsome's revenue projections suggest potential growth. The price-to-sales ratio of 16.72 shows that investors are willing to pay $16.72 for every dollar of sales, reflecting confidence in the company's future prospects.
The enterprise value to sales ratio of 16.53 aligns closely with the price-to-sales ratio, indicating a consistent valuation in relation to revenue. However, the enterprise value to operating cash flow ratio of -91.91 highlights negative operating cash flow, a concern for investors.
Axsome's debt-to-equity ratio of 2.96 suggests a relatively high level of debt compared to equity, which could impact financial stability. However, a current ratio of 1.57 indicates a reasonable level of liquidity to cover short-term liabilities, providing some reassurance to investors.
